
Oncology
Anktiva Expands for Papillary-Only Bladder Cancer
The FDA expanded Anktiva plus BCG to adults with BCG-unresponsive, high-grade papillary non-muscle-invasive bladder cancer without carcinoma in situ.
Rayan Salih · November 13, 2026 · 6 min
Stories from people navigating non-muscle-invasive bladder cancer — diagnosis, treatment, caregiving, and the ordinary days in between.
1 story

Oncology
The FDA expanded Anktiva plus BCG to adults with BCG-unresponsive, high-grade papillary non-muscle-invasive bladder cancer without carcinoma in situ.
Rayan Salih · November 13, 2026 · 6 min
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.